[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2872 Introduced in House (IH)]
114th CONGRESS
1st Session
H. R. 2872
To amend the Controlled Substances Act to modernize the treatment of
opioid addiction, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 24, 2015
Mr. Bucshon (for himself and Mr. Womack) introduced the following bill;
which was referred to the Committee on Energy and Commerce, and in
addition to the Committee on the Judiciary, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To amend the Controlled Substances Act to modernize the treatment of
opioid addiction, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Opioid Addiction Treatment
Modernization Act''.
SEC. 2. FINDINGS.
The Congress finds that opioid addiction has become a public health
epidemic that must be addressed by increasing awareness and access to
all treatment options for opioid addiction, overdose reversal, and
relapse prevention.
SEC. 3. OPIOID ADDICTION TREATMENT MODERNIZATION.
(a) In General.--Section 303(g) of the Controlled Substances Act
(21 U.S.C. 823(g)) is amended--
(1) by adding at the end the following:
``(3) The standards under paragraph (1)(A) (for determining whether
a practitioner is qualified to engage in the treatment with respect to
which registration is sought) shall include a requirement for
completion, every 2 years, of training--
``(A) provided (through classroom situations, seminars at
professional society meetings, electronic communications, or
otherwise) by an organization such as the American Society of
Addiction Medicine, the American Academy of Addiction
Psychiatry, the American Medical Association, the American
Osteopathic Association, the American Psychiatric Association,
the American Association for the Treatment of Opioid
Dependence, the National Council for Behavioral Health, or any
other organization that the Secretary determines is
appropriate; and
``(B) addressing--
``(i) opioid detoxification;
``(ii) appropriate clinical use of all drugs
approved by the Food and Drug Administration for the
treatment of opioid addiction;
``(iii) the need for initial and periodic
assessments of each patient;
``(iv) the development of an individualized
treatment plan for each patient; and
``(v) the importance of providing overdose reversal
and relapse prevention, and appropriate counseling and
other services.'';
(2) in paragraph (2)(B), by inserting ``and annually
thereafter,'' after ``before the initial dispensing of narcotic
drugs in schedule III, IV, or V or combinations of such drugs
to patients for maintenance or detoxification treatment,'';
(3) by amending paragraph (2)(B)(ii) to read as follows:
``(ii) With respect to patients to whom the practitioner
will provide such drugs or combinations of drugs, the
practitioner has the capacity to provide directly or by
referral--
``(I) all drugs approved by the Food and Drug
Administration for the treatment of opioid addiction,
including, as available, opioid maintenance,
detoxification, and overdose reversal and relapse
prevention; and
``(II) appropriate counseling and ancillary
services.'';
(4) by redesignating clause (iii) of paragraph (2)(B) as
clause (iv);
(5) after paragraph (2)(B)(ii), by inserting the following:
``(iii) The practitioner maintains a diversion control plan
that contains specific measures to reduce the likelihood of the
diversion of controlled substances prescribed by the
practitioner for the treatment of opioid addiction.'';
(6) by amending paragraph (2)(G)(ii) to read as follows:
``(ii) The term `qualifying physician' means a
physician who meets the following:
``(I) The physician is licensed under State
law.
``(II) The physician meets one or more of
the following conditions:
``(aa) The physician holds a
subspecialty board certification in
addiction psychiatry from the American
Board of Medical Specialties.
``(bb) The physician holds an
addiction certification from the
American Society of Addiction Medicine.
``(cc) The physician holds a
subspecialty board certification in
addiction medicine from the American
Osteopathic Association.
``(dd) The physician has
participated as an investigator in one
or more clinical trials leading to the
approval of a narcotic drug in schedule
III, IV, or V for maintenance or
detoxification treatment or the
approval of a drug for the treatment of
opioid addiction, as demonstrated by a
statement submitted to the Secretary by
the sponsor of such approved drug.
``(ee) The physician has such other
training or experience as the State
medical licensing board (of the State
in which the physician will provide
maintenance or detoxification
treatment) considers to demonstrate the
ability of the physician to treat and
manage opiate-dependent patients.
``(ff) The physician has such other
training or experience as the Secretary
considers to demonstrate the ability of
the physician to treat and manage
opiate-dependent patients. Any criteria
of the Secretary under this item shall
be established by regulation. Any such
criteria are effective only for 3 years
after the date on which the criteria
are promulgated, but may be extended
for such additional discrete 3-year
periods as the Secretary considers
appropriate for purposes of this item.
Such an extension of criteria may only
be effectuated through a statement
published in the Federal Register by
the Secretary during the 30-day period
preceding the end of the 3-year period
involved.
``(iii) The physician completes, with respect to
the treatment and management of opiate-dependent
patients, not less than 8 hours of training described
in paragraph (3) not less frequently than every 2
years.
``(iv) The physician obtains in writing from each
patient a signed acknowledgment that the patient--
``(I) will be subject to medication
adherence and substance use monitoring;
``(II) understands available treatment
options, including drugs approved by the Food
and Drug Administration for the treatment of
opioid addiction and their potential risks and
benefits; and
``(III) has an individualized treatment
plan.''; and
(7) by amending paragraph (2)(H)(ii) to read as follows:
``(ii) Not later than one year after the date of enactment
of the Opioid Addiction Treatment Modernization Act, the
Secretary shall update the treatment improvement protocol
containing best practice guidelines for the treatment of
opiate-dependent patients. The Secretary shall update such
protocol in consultation with the Director of the National
Institute on Drug Abuse, the Administrator of the Drug
Enforcement Administration, the Commissioner of Food and Drugs,
the Administrator of the Substance Abuse and Mental Health
Services Administration, and other substance abuse disorder
professionals. Updates to the protocol shall be guided by
science.''.
(b) Inspection Authority.--The Secretary of Health and Human
Services or the Attorney General of the United States may inspect
persons that are registered under section 303(g) of the Controlled
Substances Act (21 U.S.C. 823(g)) to ensure compliance with the
requirements in this Act (and the amendments made by this Act) with
respect to which noncompliance may result in a revocation or suspension
of the practitioner's registration.
(c) Certification of Compliance.--Not later than 1 year after the
date of enactment of this Act, all practitioners who, as of such date
of enactment, are permitted to dispense narcotic drugs to individuals
(for maintenance treatment or detoxification treatment) pursuant to
paragraph (1) or (2) of section 303(g) of the Controlled Substances Act
(21 U.S.C. 823(g)) shall submit a certification to the Secretary of
Health and Human Services of compliance with the provisions of such
section 303(g), as amended by this Act.
(d) Reports to Congress.--
(1) In general.--Not later than 1 year after the date of
enactment of this Act, and every 5 years thereafter, the
Comptroller General of the United States shall--
(A) perform a thorough review of the provision of
opioid addiction treatment services in the United
States; and
(B) submit a report to the Congress on the findings
and conclusions of such review.
(2) Contents.--Each report under paragraph (1) shall
include--
(A) an assessment of compliance with the
requirements of section 303(g) of the Controlled
Substances Act, as amended by this Act;
(B) a description of the measures taken by the
Secretary of Health and Human Services to ensure such
compliance; and
(C) an assessment of--
(i) whether the full range of science- and
evidence-based treatment options for opioid
addiction are fully integrated into treatment;
and
(ii) the circumstances surrounding
medication diversion and misuse.
<all>